125 related articles for article (PubMed ID: 22226877)
21. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
Son S; Lim SM; Chae SY; Kim K; Park EJ; Lee KC; Na DH
Int J Pharm; 2015 Nov; 495(1):81-86. PubMed ID: 26325318
[TBL] [Abstract][Full Text] [Related]
22. Trimeric PEG-Conjugated Exendin-4 for the Treatment of Sepsis.
Lee W; Park EJ; Kwak S; Lee KC; Na DH; Bae JS
Biomacromolecules; 2016 Mar; 17(3):1160-9. PubMed ID: 26905040
[TBL] [Abstract][Full Text] [Related]
23. Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.
Sasson K; Marcus Y; Lev-Goldman V; Rubinraut S; Fridkin M; Shechter Y
J Control Release; 2010 Mar; 142(2):214-20. PubMed ID: 19883707
[TBL] [Abstract][Full Text] [Related]
24. Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving
Tian H; Chang M; Lyu Y; Dong N; Yu N; Yin T; Zhang Y; He H; Gou J; Tang X
Expert Opin Drug Deliv; 2024; 21(1):169-185. PubMed ID: 38224039
[TBL] [Abstract][Full Text] [Related]
25. Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution.
Ueda T; Ito T; Tomita K; Togame H; Fumoto M; Asakura K; Oshima T; Nishimura S; Hanasaki K
Bioorg Med Chem Lett; 2010 Aug; 20(15):4631-4. PubMed ID: 20576431
[TBL] [Abstract][Full Text] [Related]
26. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.
Son S; Chae SY; Kim CW; Choi YG; Jung SY; Lee S; Lee KC
J Med Chem; 2009 Nov; 52(21):6889-96. PubMed ID: 19827752
[TBL] [Abstract][Full Text] [Related]
27. PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.
Sun Z; Tong G; Kim TH; Ma N; Niu G; Cao F; Chen X
Theranostics; 2015; 5(3):240-50. PubMed ID: 25553112
[TBL] [Abstract][Full Text] [Related]
28. Newly designed modifier prolongs the action of short-lived peptides and proteins by allowing their binding to serum albumin.
Shechter Y; Sasson K; Lev-Goldman V; Rubinraut S; Rubinstein M; Fridkin M
Bioconjug Chem; 2012 Aug; 23(8):1577-86. PubMed ID: 22759320
[TBL] [Abstract][Full Text] [Related]
29. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
Roan JN; Cheng HN; Young CC; Lee CJ; Yeh ML; Luo CY; Tsai YS; Lam CF
J Surg Res; 2017 Feb; 208():93-103. PubMed ID: 27993221
[TBL] [Abstract][Full Text] [Related]
30. Controlling of systemic absorption of gliclazide through incorporation into alginate beads.
Al-Kassas RS; Al-Gohary OM; Al-Faadhel MM
Int J Pharm; 2007 Aug; 341(1-2):230-7. PubMed ID: 17507189
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris.
Huang YS; Chen Z; Chen YQ; Ma GC; Shan JF; Liu W; Zhou LF
J Pept Sci; 2008 May; 14(5):588-95. PubMed ID: 17994612
[TBL] [Abstract][Full Text] [Related]
32. Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
Zhong X; Yang S; Liu T; Ji S; Hu J; Li H
Eur J Med Chem; 2018 Apr; 150():841-850. PubMed ID: 29597167
[TBL] [Abstract][Full Text] [Related]
33. An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.
Kim D; Jeon H; Ahn S; Choi WI; Kim S; Jon S
J Control Release; 2017 Jun; 256():114-120. PubMed ID: 28457895
[TBL] [Abstract][Full Text] [Related]
34. Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.
Xue S; Wasserfall C; Parker M; McGrail S; McGrail K; Campbell-Thompson M; Schatz DA; Atkinson MA; Haller MJ
J Diabetes Complications; 2010; 24(3):163-7. PubMed ID: 19217320
[TBL] [Abstract][Full Text] [Related]
35. Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.
Liang Y; Qiu H; Glinka Y; Lazarus AH; Ni H; Prud'homme GJ; Wang Q
J Gene Med; 2011 Sep; 13(9):470-7. PubMed ID: 21786368
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
37. Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes.
Kong JH; Oh EJ; Chae SY; Lee KC; Hahn SK
Biomaterials; 2010 May; 31(14):4121-8. PubMed ID: 20149450
[TBL] [Abstract][Full Text] [Related]
38. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
Ahn S; Lee IH; Lee E; Kim H; Kim YC; Jon S
J Control Release; 2013 Sep; 170(2):226-32. PubMed ID: 23747732
[TBL] [Abstract][Full Text] [Related]
39. Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin-4 injected animals.
Malendowicz LK; Nowak KW
Int J Mol Med; 2002 Sep; 10(3):327-31. PubMed ID: 12165809
[TBL] [Abstract][Full Text] [Related]
40. Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin.
Zhang Y; Wei W; Lv P; Wang L; Ma G
Eur J Pharm Biopharm; 2011 Jan; 77(1):11-9. PubMed ID: 20933083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
